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1518Idarucizumab, a Speciﬁc
Dabigatran Reversal
Agent, Reduces Blood
Loss in a Porcine Model of
Trauma With Dabigatran
AnticoagulationIdarucizumab is a humanized antibody fragment that
speciﬁcally reverses dabigatran and provides immedi-
ate and sustained reversal of dabigatran anticoagu-
lation (1–3). However, its effect on life-threatening1 Effects of Post-Trauma Idarucizumab in Animals
With Dabigatran
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d unbound dabigatran (solid line) are shown. Total dabigatran in-
oth bound (inactive) and unbound (active) molecules. The dashed
line (t ¼ 0) indicates time of liver injury, and the dotted vertical line
s the time of intervention (t ¼ 15 min). Data are shown as mean  SD,
roup, *p < 0.05 versus all groups. IDA ¼ idarucizumab.bleeding following major trauma has not been stud-
ied. Thus, we investigated whether idarucizumab re-
verses dabigatran anticoagulation in a lethal porcine
blunt liver injury model.
After obtaining ethical approval, male pigs (mean
weight 42 kg) received oral dabigatran etexilate 30
mg/kg twice daily for 3 days and dabigatran infusion
for 90 min on day 4 (n ¼ 24) or placebo (n ¼ 6). On day
4, all 30 pigs underwent surgery under anesthesia
(4). Dabigatran-treated animals were randomized to
intervention with idarucizumab 30, 60, or 120 mg/kg
or saline control. Standardized blunt liver injury was
induced, and 15 min post-injury, idarucizumab or
saline was administered intravenously. Blood loss
and coagulation parameters were recorded for
240 min post-trauma or until death. Plasma levels
of dabigatran and idarucizumab were measured
using liquid chromatography-mass spectrometry and
enzyme-linked immunosorbent assay. Data were
assessed using analysis of variance and presented as
mean  SD. All p values <0.05 were considered
signiﬁcant.
Anticoagulation with dabigatran approximately
doubled blood loss during the ﬁrst 12 min post-
trauma (786  39 ml vs. 409  53 ml, p < 0.0001)
(Figure 1A). Subsequently, among control animals
(dabigatran/saline), blood loss increased over time to
2,977  316 ml. In comparison, idarucizumab 30, 60,
and 120 mg/kg signiﬁcantly decreased total blood loss
to 1,586  619 ml, 1,065  97 ml, and 1,140  109 ml,
respectively (reductions of 47%, 64%, and 62%,
respectively) (Figure 1A). All control animals died
early (121  26 min), compared with 1 of 6 in the
idarucizumab 30 mg/kg group. Survival in the re-
maining idarucizumab animals was 100%.
Dabigatran signiﬁcantly prolonged plasma-based
clotting tests versus sham before trauma, for ex-
ample, activated partial thromboplastin time (aPTT)
61  17 s versus 13  1 s at baseline. Idarucizumab
reduced the aPTT dose dependently. For example, at
60 min post-trauma the aPTT was 40  11 s, 28  7 s,
and 16  1 s for 30, 60, and 120 mg/kg, respectively;
this effect was immediate and was maintained over
time.
Thrombin generation at baseline was 302  47
nm$min (endogenous thrombin potential) and was
completely inhibited by dabigatran, 0  0 nm$min.
The ETP increased dose-dependently after idar-
ucizumab; for example, at 60 min post-trauma, 30,
60, and 120 mg/kg resulted in thrombin generation of
131  38 nm$min, 212  42 nm$min, and 372 
42 nm$min versus 353  42 nm$min in the sham
group. Similarly, all coagulation tests were restored
to baseline, with the highest dose of 120 mg/kg
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sures for dabigatran, whereas the aPTT provides an
approximate assessment. All tests showed similar
patterns of reversal, consistent with observations in
healthy volunteers (2).
Peak dabigatran concentration on day 4 was 1,161 
372 ng/ml just before injury. There was a large in-
crease in total plasma dabigatran after idarucizumab
administration (Figure 1B), without increased anti-
coagulation. Total dabigatran includes molecules
bound to idarucizumab or plasma proteins and un-
bound (active) molecules. Idarucizumab remains
predominantly in plasma, and this initiates a shift in
equilibrium of dabigatran molecules from tissues to
the blood compartment where they bind to idaru-
cizumab. The process continues until idarucizumab
becomes saturated with dabigatran or all active dabi-
gatran is bound, as with 120 mg/kg idarucizumab. No
further anticoagulant activity was observed with the
120 mg/kg dose, suggesting that the idarucizumab–
dabigatran complex remains stable and the 2 drugs are
cleared together.
Post-mortem macroscopic evaluation of the heart,
lungs, kidneys, and liver showed no evidence
of thromboembolism. However, limitations of this
study such as the high dabigatran concentrations
and species differences between humans and pigs
must be considered. Clinical trials are warranted to
conﬁrm whether our results are applicable to patients.
This study demonstrates that idarucizumab re-
duces dabigatran-associated bleeding and mortality
in a porcine trauma model. Treatment with idaru-
cizumab stopped bleeding within 15 min and was
associated with an immediate decrease in dabiga-
tran anticoagulant effects. There was no evidence of
safety concerns associated with the administration
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Left Ventricular Size Is
Critical for the
Echocardiographic
Assessment of Chronic
Severe Mitral RegurgitationWe read with great interest the recent paper by
Uretsky et al. (1), who showed that there was only
limited agreement between echocardiographic and
magnetic resonance imaging (MRI) in the assess-
ment of mitral regurgitation (MR). MRI assessment
was more reproducible and more predictive than
echocardiography for left ventricular (LV) reverse
remodeling after mitral surgery. Echocardiographic
evaluation of MR was performed using an integrated
approach based on proximal isovelocity surface area
(PISA), effective regurgitant oriﬁce area, vena con-
tracta, left atrial and LV size, pulmonary vein ﬂow
pattern, and MR Doppler jet characteristics such as
color Doppler area, eccentricity, and temporal varia-
tion. MR volume was calculated using the PISA
method for all patients.
Of 38 patients classiﬁed with severe MR by echo-
cardiography, MRI classiﬁed 12 as severe, yielding
a 32% concordance. On further analysis of data pro-
vided in the manuscript we found that in the subset
of patients with LV end-diastolic diameter (LVEDD)
$55 mm MRI correctly identiﬁed 11 of 19 patients as
